(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
From Overpowered to Coordinated: Individual Accounts of Cleaning up - 2Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- 3Step by step instructions to Show Children the Significance of Appropriate Handshaking
- 4Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- 5‘Wu-Tang Forever: The Final Chamber’ tour — How to get tickets, presale times, concert dates and more
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- One-third of asylum applications by Iranians approved in Germany
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- The Way to Monetary Health: Individual budget Change
- Banks for High Fixed Store Rates: Augment Your Investment funds
- Vote In favor of Your Favored Language Interpretation Administration
- Three arrested in Paris after attempted bomb attack outside Bank of America
- The Force of Care: Living with Goal
- James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
